PharmaBoardroom

IFPMA’s Thomas Cueni on the Value of Business Ethics for…

Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers…

Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the…

Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies…

Artificial Intelligence Can Save Pharmacovigilance in Australia

Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health,…

China: Emerging Pharmacovigilance Framework Ensuring Safe…

PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective…

Africa’s Renewed Hope for Drug Discovery and Health Innovation

Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind…

J.P. Morgan Healthcare Conference 2022: Glass Half Full

David H. Crean summarizes the recent 40th annual J.P. Morgan Healthcare Conference 2022 that was held in a virtual format. Crean underlines the…

PharmaBoardroom’s Top 5 Executive Insights 2021

2021 saw PharmaBoardroom’s network of executives and experts weighing in on some of the most pressing issues facing our industry today. See below…

EUnetHTA 21 Launches Joint Scientific Consultations for…

Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA…

Key Features of Orphan Drug Registration in Singapore, Malaysia,…

Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of…

The Cell & Gene Therapy Market: Excitement Abounds

David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal…

PharmaBoardroom’s Top Five Op-Eds of 2021

PharmaBoardroom's network of thought leaders provided some of our best-read content in 2021 on topics ranging from China's National Reimbursement Drug…

The Global Pandemic Agreement: Time to Get Serious

Shawview Consulting's Brendan Shaw laments the descent into nationalism that COVID-19 - like past pandemics - has led to, and outlines his hopes that…

Tagged with Opinion